June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
SOCS3 inhibits pathologic angiogenesis
Author Affiliations & Notes
  • Jean-Sebastien Joyal
    Ophthalmology, Children's Hospital, Harvard Med Sch, Boston, MA
  • Andreas Stahl
    Ophthalmology, University Eye Hospital Freiburg, Freiburg, Germany
  • Ye Sun
    Ophthalmology, Children's Hospital, Harvard Med Sch, Boston, MA
  • Zhuo Shao
    Ophthalmology, Children's Hospital, Harvard Med Sch, Boston, MA
  • Zhongjie Fu
    Ophthalmology, Children's Hospital, Harvard Med Sch, Boston, MA
  • Aimee Juan
    Ophthalmology, Children's Hospital, Harvard Med Sch, Boston, MA
  • Dorothy Pei
    Ophthalmology, Children's Hospital, Harvard Med Sch, Boston, MA
  • Christian Hurst
    Ophthalmology, Children's Hospital, Harvard Med Sch, Boston, MA
  • Jing Chen
    Ophthalmology, Children's Hospital, Harvard Med Sch, Boston, MA
  • Lois Smith
    Ophthalmology, Children's Hospital, Harvard Med Sch, Boston, MA
  • Footnotes
    Commercial Relationships Jean-Sebastien Joyal, None; Andreas Stahl, None; Ye Sun, None; Zhuo Shao, None; Zhongjie Fu, None; Aimee Juan, None; Dorothy Pei, None; Christian Hurst, None; Jing Chen, None; Lois Smith, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 5574. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jean-Sebastien Joyal, Andreas Stahl, Ye Sun, Zhuo Shao, Zhongjie Fu, Aimee Juan, Dorothy Pei, Christian Hurst, Jing Chen, Lois Smith; SOCS3 inhibits pathologic angiogenesis. Invest. Ophthalmol. Vis. Sci. 2013;54(15):5574. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Massive upregulation of inflammatory mediators and growth factors drive pathologic angiogenesis whereas physiologic angiogenesis is more controlled. SOCS3 is an inducible negative feedback regulator acting downstream of both cytokines and growth factor signaling. We hypothesized that SOCS3 might act as an endogenous angiostatic to modulate pathological blood vessel growth.

Methods: Using a Cre/Lox system, we deleted SOCS3 in vessels and studied developmental and pathologic angiogenesis in murine models of oxygen-induced retinopathy (OIR) and cancer.

Results: Conditional loss of SOCS3 leads to increased pathologic neovascularization, resulting in pronounced retinopathy and increased tumor size. In contrast, physiologic vascularization is not regulated by SOCS3. In vitro, SOCS3 knockdown increases proliferation and sprouting of endothelial cells co-stimulated with EPO and TNFα via reduced feedback inhibition of the STAT3 and mTOR pathways. Reintroducing SOCS3 curbs tumor growth and pathologic angiogenesis.

Conclusions: These results identify SOCS3 as a pivotal endogenous feedback inhibitor of angiogenesis that is specifically induced in pathologic states, but not in physiologic angiogenesis. Acting at the converging crossroads of growth factor- and cytokine-induced angiogenesis, SOCS3 is a potential therapeutic target to treat angiogenic disorders like proliferative retinopathies and cancer.

Keywords: 557 inflammation • 700 retinal neovascularization • 706 retinopathy of prematurity  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×